Granules India Ltd. Announces Q1FY26 Financial Results
Hyderabad: Granules India Ltd., a vertically integrated pharmaceutical company, has announced its financial results for the quarter ended June 30, 2025. The company reported revenue from operations of INR 12,101 Mn, up 3% YoY, driven largely by sales growth in North America.
Financial Highlights
EBITDA before exceptional items stood at INR 2,467 Mn, down 5% YoY, while PBT before exceptional items was INR 1,704 Mn, down 6% YoY. PAT after exceptional items was INR 1,126 Mn, down 16% YoY. The company’s ROCE was 16.0%, and net debt stood at INR 9,480 Mn.
Business Update
The company’s product mix for Q1FY26 consisted of API (14%), PFI (10%), Finished Dosages (74%), and Peptides/CDMO (2%). Granules India successfully completed USFDA audits at its Bonthapally API facility and other sites, and the Danish Medicines Agency granted certification after an EU GMP inspection of the Gagillapur facility.
Future Outlook
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, expressed optimism about the company’s long-term growth prospects, citing progress on the Gagillapur remediation program and the integration of Senn Chemicals through the Ascelis platform in the CDMO sector.
